GWM Advisors LLC lifted its position in Boston Scientific Co. (NYSE:BSX) by 17.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,357 shares of the medical equipment provider’s stock after buying an additional 1,364 shares during the period. GWM Advisors LLC’s holdings in Boston Scientific were worth $402,000 as of its most recent SEC filing.
Several other institutional investors have also recently modified their holdings of the company. Dimensional Fund Advisors LP grew its holdings in Boston Scientific by 1.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,978,445 shares of the medical equipment provider’s stock worth $105,251,000 after acquiring an additional 51,606 shares during the period. Geode Capital Management LLC grew its holdings in Boston Scientific by 11.3% during the 4th quarter. Geode Capital Management LLC now owns 16,982,002 shares of the medical equipment provider’s stock worth $599,030,000 after acquiring an additional 1,724,046 shares during the period. BB&T Corp grew its holdings in Boston Scientific by 18.0% during the 1st quarter. BB&T Corp now owns 52,680 shares of the medical equipment provider’s stock worth $2,022,000 after acquiring an additional 8,024 shares during the period. Mercer Global Advisors Inc. ADV acquired a new stake in Boston Scientific during the 1st quarter worth about $395,000. Finally, Exane Derivatives grew its holdings in Boston Scientific by 2,862.5% during the 1st quarter. Exane Derivatives now owns 34,483 shares of the medical equipment provider’s stock worth $1,323,000 after acquiring an additional 33,319 shares during the period. 89.30% of the stock is currently owned by hedge funds and other institutional investors.
In related news, SVP Jodi Euerle Eddy sold 7,803 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $38.42, for a total value of $299,791.26. Following the transaction, the senior vice president now owns 88,978 shares of the company’s stock, valued at approximately $3,418,534.76. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Xin Warren Wang sold 10,000 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $38.45, for a total transaction of $384,500.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 63,289 shares of company stock valued at $2,611,790. 0.66% of the stock is currently owned by company insiders.
Shares of BSX opened at $42.48 on Friday. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.31 and a quick ratio of 1.04. The stock has a 50-day moving average of $42.50 and a 200-day moving average of $39.79. The company has a market cap of $59.47 billion, a PE ratio of 28.90, a P/E/G ratio of 2.54 and a beta of 0.80. Boston Scientific Co. has a one year low of $31.56 and a one year high of $43.66.
Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.39 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.38 by $0.01. The company had revenue of $2.63 billion during the quarter, compared to the consensus estimate of $2.64 billion. Boston Scientific had a return on equity of 23.29% and a net margin of 13.85%. The firm’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period last year, the business posted $0.41 EPS. Analysts expect that Boston Scientific Co. will post 1.56 EPS for the current fiscal year.
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Recommended Story: The Discount Rate – What You Need to Know
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.